Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Pfizer, Medivation Terminate Dimebon Development After Failed Alzheimer’s Trial

Drug Industry Daily

Jan. 18, 2012 | Vol. 11 No. 12

Pfizer, Medivation Terminate Dimebon Development After Failed Alzheimer’s Trial

Pfizer and Medivation are discontinuing their co-development of Dimebon in all indications after another late-stage Alzheimer’s trial missed its primary endpoints.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Lilly Phase III Non-Hodgkin’s Lymphoma Drug Trial Halted Boehringer Ingelheim’s NSCLC Candidates Get Mixed Results Rise in Global Trial Recruitment Raises Ethics, Compliance Concerns in EU Lilly Halts Phase III Trial of Non-Hodgkin’s Lymphoma Candidate

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.